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NetB toxin from Clostridium perfringens is a major virulence factor in necrotic enteritis in poultry. In this study the
efficacy of NetB as a vaccine antigen to protect chickens from necrotic enteritis was examined. Broiler chickens
were immunized subcutaneously with purified recombinant NetB (rNetB), formalin treated bacterin and cell free
toxoid with or without rNetB supplementation. Intestinal lesion scores and NetB antibody levels were measured to
determine protection after mild oral gavage, moderate in-feed and heavy in-feed challenges with virulent C.
perfringens isolates. Birds immunized with rNetB were significantly protected against necrotic enteritis when
challenged with a mild oral dose of virulent bacteria, but were not protected when a more robust challenge was
used. Bacterin and cell free toxoid without rNetB supplementation did not protect birds from moderate and severe
in-feed challenge. Only birds immunized with bacterin and cell free toxoid supplemented with rNetB showed
significant protection against moderate and severe in-feed challenge, with the later giving the greatest protection.
Higher NetB antibody titres were observed in birds immunized with rNetB compared to those vaccinated with
bacterin or toxoid, suggesting that the in vitro levels of NetB produced by virulent C. perfringens isolates are too
low to induce the development of a strong immune response. These results suggest that vaccination with NetB
alone may not be sufficient to protect birds from necrotic enteritis in the field, but that in combination with other
cellular or cell-free antigens it can significantly protect chickens from disease.Introduction
Necrotic enteritis in chickens is a common bacterial dis-
ease that costs the global poultry production industry an
estimated US$2 billion annually [1]. The causative agent
is the bacterium Clostridium perfringens. Currently,
ionophore anticoccidials or antibiotic growth promoters
are used to control necrotic enteritis [2]. However, the
risk of antibiotic resistance and consumer pressure has
prompted the industry to reduce the use of in-feed anti-
biotics and it is likely that the use of ionophore
anticoccidials will also be reduced. In the European
Union, the use of most antibiotic growth promotants
has been banned, and necrotic enteritis remains an on-
going issue for producers in these countries [3,4]. This
situation has increased the need to develop other* Correspondence: anthony.keyburn@csiro.au
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reproduction in any medium, provided the ormethods to control necrotic enteritis in poultry. Vaccin-
ation is an alternative approach that could be deployed
to manage necrotic enteritis in the absence of antibiotics
and anticoccidials.
Vaccines against other clostridial diseases in produc-
tion animals have been widely and successfully used for
many years and are based on protection from specific
toxins produced by the bacteria that are associated with
the particular disease [5]. Necrotic enteritis in chickens
is a notable exception; it is an economically important
clostridial disease for which there are limited vaccines
available. Although necrotic enteritis has been recognised
as a significant clostridial disease of chickens for 50 years
[6], progress towards the development of a vaccine has
been very limited until recently. Historically, C. perfringens
alpha-toxin was implicated as the major virulence factor
in the disease, which led to vaccine development efforts
based around this toxin. Several experimental vaccines
based on alpha-toxin have been reported and they have
had variable protective success [7-9]. However, an alpha-l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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shown to retain full virulence [10], indicating that the
toxin is not an essential virulence factor. Despite this
observation it is clear that antibodies raised against this
toxin can partially protect birds from disease. Although
alpha-toxin is a secreted protein, Zekarias et al. [9] have
shown that some of the protein remains associated with
the cell membrane. It is presumably immune interaction
with this cell-associated protein that provides the
protective effect seen with some alpha-toxin based
vaccines. The fact that vaccines using live attenuated
alpha-toxin negative strains of C. perfringens are effect-
ive against avian necrotic enteritis [11] demonstrates
that there must be other antigens of C. perfringens that
are capable of inducing a protective immune response.
Some of these protective antigens have been identified
in recent studies [12,13].
Recently, a secreted β-pore forming toxin, NetB, has
been isolated from a virulent chicken isolate of C.
perfringens and shown to be essential for disease induc-
tion [14]. NetB toxin has been found in most C.
perfringens isolates from necrotic enteritis-diseased
birds, but is uncommon in isolates recovered from
healthy birds [15-17]. As an important virulence factor,
NetB represents an attractive vaccine candidate, as
shown in a recent study where vaccination with NetB in-
duced some protection of broiler birds against experi-
mental necrotic enteritis [18]. The studies reported here
not only test whether NetB can be used as a protective
vaccine antigen as a single subunit vaccine, but investi-
gate whether NetB in combination with other antigenic
proteins, either whole cell bacterin or secreted C.




C. perfringens strains EHE-NE18 [10] and WER-NE36
were used as challenge strains in the in vivo necrotic en-
teritis disease induction models described below. EHE-
NE18 (Type A, netB+) has been previously shown [10]
to be virulent in an in vivo model while WER-NE36
(Type A, netB+) was isolated recently from a clinical case
and shown to be highly virulent in our disease models.
Vaccine preparation and delivery
A single EHE-NE18 colony from a Tryptose Sulphite Cy-
closerine agar plate (TSC agar, Oxoid, Basingstoke,
United Kingdom) was inoculated into 20 mL of
Trypticase-peptone-glucose (TPG) medium and grown
overnight at 37°C. Ten mL of the resultant culture were
inoculated into one litre of TPG medium and grown at
37°C to an OD600nm of 0.8 – 1.0. The culture was
centrifuged at 6000 g for 10 min at 4°C, filtered througha 0.45 μm membrane and concentrated by ultrafiltra-
tion through a 10 kDa membrane (Merck Millipore,
Massachusetts, USA) to 40 mL (25×). The bacterial
cells were resuspended in 40 mL of phosphate buffered
saline (PBS; 137 mM NaCl, 10 mM phosphate, 2.7 mM
KCl, pH 7.4) and sonicated (three times for 30 s) to dis-
rupt the cellular membranes and release cytoplasmic
proteins. Formaldehyde (40%) was added to both the
concentrated supernatant and the cells to a final con-
centration of 0.3% (v/v). Bacterin comprised 50:50 (v/v)
bacterial cells and culture supernatant, while toxoid
consisted of formaldehyde-treated culture supernatant
only.
Recombinant NetB (rNetB) was expressed and purified
(98% purity) as previously described [14] and formalin
treated as described above. Fifty μg of rNetB per bird
was used for NetB subunit, bacterin- and toxoid-
supplemented vaccines. Each bird was vaccinated sub-
cutaneously at day 7 and day 17 using CSIRO triple
adjuvant [19] (comprising 60% (v/v) Montanide, 40%
(v/v) antigen combined with Quil A, 3 mg/mL, and DEAE-
dextran, 30 mg/mL in PBS) in a total volume of 500 μL.
Necrotic enteritis disease induction models
Two different challenge methods were used: a direct oral
gavage challenge with small volumes of culture, which
may be more akin to challenges that occur in the field,
and a large volume in-feed challenge that gives a more
robust challenge, resulting in higher levels of disease in a
greater percentage of birds. These oral gavage and in-
feed necrotic enteritis disease induction models were
performed essentially as previously described [10,20],
with some modification to the timing to fit in with vac-
cination schedules. Briefly, groups of 10 chickens were
kept in adjacent, but separate, pens in an animal isola-
tion facility. Commercial 1-day-old Ross 308 broiler
chickens were fed an antibiotic-free chicken starter diet
containing 20% (w/w) protein for 22 days. On the morn-
ing of day 23 the feed was changed to a high protein
wheat-based feed containing 50% fishmeal. On day 28,
chickens were euthanized with inhaled carbon dioxide
and their small intestines (duodenum to ileum) exam-
ined for gross necrotic lesions. Intestinal lesions in the
small intestine were scored as before [10]: 0 = no gross
lesions; 1 = thin or friable walls; 2 = focal necrosis or ul-
ceration (1–5 foci); 3 = focal necrosis or ulceration (6–
15 foci); 4 = focal necrosis or ulceration (16 or more
foci); 5 = patches of necrosis 2–3 cm long; 6 = diffuse
necrosis typical of field cases. The statistical significance
of differences between groups was assessed using
Kruskal-Wallis one-way ANOVA. All animal experi-
ments were assessed, approved and monitored by the
Australian Animal Health Laboratory’s Animal Ethics
Committee. Experimental models of C. perfringens
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of predisposing factors. The most widely published
models either use high protein feed or Eimeria infection.
Eimeria infection can cause immunological stress, which
may be inappropriate in a vaccine study. Therefore, we
chose to use high protein as the predisposing factor in
this study.
Oral gavage challenge
For the oral gavage challenge, C. perfringens strain EHE-
NE18 was grown in fluid thioglycollate broth (FTG;
Difco) with the addition of 2% (w/v) soluble starch and
1.5% (w/v) thiopeptone and incubated at 37°C for 14 h.
On the evening of day 24 the feed was withdrawn and
each bird was orally challenged with 1.5 mL of C.
perfringens culture (109 to 1010 CFU). On day 25 birds
were again orally challenged and feed contaminated with
C. perfringens (1:10 (v/w) culture to feed) was
administered.
In-feed challenge
For the in-feed challenge, 1–2 C. perfringens (EHE-NE18
or WER-NE36) colonies grown on TSC agar were trans-
ferred into 10 mL of cooked meat medium (CMM; Difco
Becton Dickinson, Maryland, USA) and incubated at
37°C for 18 h. One mL of the resulting culture was used
to inoculate 20 mL of FTG, and, after incubation at 37°C
for 18 h, 1 mL was used to inoculate 20 mL of CMM
and incubated at 37°C for 18 h. Twenty mL of the final
CMM culture was used as the inoculum for 800 mL of
FTG medium, and after 18 h incubation at 37°C, the cul-
ture was mixed with feed for the challenge. A separate
serially passed culture was prepared for each challenge
feeding (n = 4). High protein-feed and FTG culture were
mixed in a ratio of 3:4 (v/w). The mixture was then
placed into feed trays. Birds were fed the culture/feed
mix twice a day on days 26 and 27. Trays were cleaned
and the remaining feed discarded prior to each subse-
quent feeding.
Experimental design
For NetB immunogenic studies two groups of 10 birds
were challenged in-feed (described above) with either
EHE-NE18 or WER-NE36. Blood samples from the wing
(brachial vein) were taken and serum collected directly
before challenge and 6 and 10 days post challenge.
Serum anti-NetB IgY levels were determined by enzyme-
linked immunosorbent assay (ELISA).
The vaccine studies were performed with the same
vaccination regime but separated into three different
challenge models; (i) oral gavage challenge with EHE-
NE18 to produce mild disease, (ii) in-feed challenge
using EHE-NE18 to produce moderate levels of disease,
and (iii) an in-feed challenge with WER-NE36 toproduce the most severe disease. For vaccine studies a
blood sample was taken from each bird, immediately fol-
lowing euthanasia, for serum analysis by ELISA and
Western blotting.
Western blotting and immunoassay detection of
antibodies
NetB-specific antibody levels were determined by the
end-point dilution method using an ELISA. Microtiter
plates (Nunc Maxsorp, Roskilde, Denmark) were coated
with rNetB protein (1 μg/mL in 0.1 M sodium carbonate
buffer, pH 9.6) for 16 h at 4°C. The coated plates were
washed twice with PBS (pH 7.6) and blocked for 3 h at
room temperature with 5% (w/v) bovine serum albumin
(BSA; Sigma Aldrich, Missouri, USA) in PBS (PBSB).
The plates were washed twice with PBS and sera from
the immunized birds, and the concurrent control
groups, diluted 1:400 in 1% BSA, were added and the
plates incubated for 1 h at 37°C. The plates were washed
5 times with PBS plus Tween 20 (0.05% (v/v), PBST)
and once with PBS before the addition of goat-anti-
chicken IgY horseradish peroxidase conjugate (KPL,
Maryland, USA) diluted 1:2000 in PBSB and incubated
for 1 h at 37°C. After extensive washing of the plates
with PBST (5×) and PBS (1×) the colour reaction was
developed by using a tetramethylbenzidine alkaline
phosphate substrate kit (Invitrogen), following the
manufacturer's instructions. The reactions were stopped
by the addition of 50 μL of 0.5 M NaOH and the ab-
sorbance at 450 nm was measured in a microplate spec-
trophotometer (BioTek). The specific antibody level of
the immune serum was expressed as the A450 value
above the cut-off [21], which was defined as the mean
absorbance value of the unimmunized plus three stand-
ard deviations.
A recombinant NetB preparation was run on SDS-
PAGE (NuPAGE® Novex 4–12% Bis-Tris gel, Invitrogen)
in MES SDS buffer (NuPAGE®MES SDS Running Buffer,
Invitrogen, California, USA). Protein was transferred
onto PDVF (Invitrogen) membrane and probed with im-
mune serum from vaccinated birds. Blots were devel-
oped with an ECL Western Blotting kit (Amersham
Biosciences, GE Life Sciences, Bunkinghamshire, United
Kingdom) and the results recorded on autoradiographic
film.
Results
NetB is immunogenic in chickens
To investigate whether in vivo produced native NetB
was able to invoke an immune response during an infec-
tion, groups of 10 birds were challenged separately, in-
feed (see material and methods for details), with two
different virulent C. perfringens strains, EHE-NE18 and
WER-NE36, and allowed to recover from the infection.
Figure 2 Western blot of serum from broiler chickens
immunized with rNetB. Recombinant NetB was electrophoresied
on a 4%-12% SDS-PAGE and transferred onto a PVDF membrane.
The blot was developed with an ECL Western blotting kit and results
recorded on autoradiographic film. SeeBlue Plus2 prestained marker
(Invitrogen) was used as a size marker (kDa). Birds were immunized
with 50 μg of rNetB with CSIRO Triple adjuvant (days 7 and 17) and
serum collected on day 28. A, probed with sera from birds
vaccinated with adjuvant only; N, probed with sera from birds
vaccinated with rNetB in adjuvant.
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challenge, was used in a NetB-specific ELISA. Pooled
serum from birds challenged with either EHE-NE18 or
WER-NE36, showed strong anti-NetB antibodies, with
the highest levels observed 6 days post challenge
(Figure 1). These results demonstrated that NetB stimu-
lates an immune response in birds that have been chal-
lenged with virulent strains.
rNetB induces a protective immune response
To determine the immunogenicity of purified rNetB,
chickens were immunized at day 7, boosted at day 17,
and oral gavage challenged with EHE-NE18 at days 24
and 25. Serum was collected at day 28 post-hatch. These
sera were tested for NetB specific antibodies using West-
ern blot analysis (Figure 2) and ELISA (Figure 3a).
Chickens immunized with rNetB had significantly higher
levels of anti-NetB IgY antibodies (p < 0.001) than birds
treated with adjuvant alone or the no treatment controls.
Western blot analysis using sera from the rNetB vacci-
nated birds showed strong antibody binding to rNetB
(33 kDa).
To determine if vaccination with rNetB can protect
birds from disease, birds were immunised with rNetB
and then challenged with pathogenic C. perfringens. Pro-
tection was assessed by the average lesion score of the
treatment groups. The rNetB vaccine provided statisti-
cally significant (p < 0.05) protection against an oral gav-
age C. perfringens challenge in comparison to the
adjuvant and no treatment control groups (Figure 4a).
There was a 58% reduction in the number of birds with
lesions and a significant reduction in the average lesion
score (65% reduction, p < 0.05) when the rNetB-
vaccinated group was compared with the combined ad-
juvant and no treatment groups.
A second, more aggressive in-feed, homologous chal-













Figure 1 NetB specific IgY production in birds inoculated with
two different C. perfringens strains. Two groups of 10 birds were
challenged in-feed (days 26 and 27) either with EHE-NE18 (●) or
WER-NE36 (■) and serum collected on days 26 (pre-bleed), 33 (6
days post-challenge, 6 DPC) and 37 (10 days post challenge, 10
DPC). The levels of serum IgY antibodies against NetB were
measured by ELISA and expressed as the average optical density at
450nm. The error bars represent SEM.protective efficacy of the rNetB vaccine. To determine if
improved efficacy could be obtained we also immunised
other birds with either whole cell bacterin or whole cell
bacterin supplemented with rNetB. The birds immunised
with rNetB or bacterin alone were not protected against
this more aggressive homologous challenge (Figure 4b).
However, birds immunised with bacterin supplemented
with rNetB had a statistically significant reduction in le-
sion scores compared to both the negative control groups
(p < 0.05), with 67% reduction in birds with lesions and
76% reduction in average lesion score. Birds immunised
with rNetB alone (Figure 3b) had the highest level of anti-
NetB IgY antibodies whereas birds immunised with bac-
terin had very low levels. Those birds immunised with
bacterin supplemented with rNetB had significantly higher
(p < 0.05) levels of anti-NetB IgY antibodies compared to
the no treatment control birds.
To determine if bacterin supplemented with rNetB















































Figure 3 Serum IgY responses of broiler chickens immunized with clostridial proteins. Chickens were immunized subcutaneously with the
indicated vaccines on days 7 and 17, challenged with C. perfringens, and the levels of serum IgY antibodies against NetB were measured by ELISA
at day 28. Adjuvant only and no treatment groups were used as controls. (a) Birds were immunized and challenged orally with EHE-NE18 (days
24 and 25). (b) Birds were immunized and challenged in-feed with EHE-NE18 (days 26 and 27). (c) Birds were immunized and challenge in-feed
with WER-NE36 (days 26 and 27). The error bars represent SEM.
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supplemented with rNetB. We also immunised chickens
with toxoid (cell free inactive proteins) and toxoid
supplemented with rNetB. The birds were challenged,
in-feed, with the most highly virulent strain available to
us, WER-NE36. Those birds immunised with either
rNetB or bacterin showed no reduction in lesion score
compared to the adjuvant control group (Figure 4c). The
group immunised with toxoid had a lower average dis-
ease score but was not statistically significantly protected
(p > 0.05). Only chickens immunised with bacterin or
toxoid supplemented with rNetB showed statistically sig-
nificant (p < 0.05) decreases in lesion score compared to
the adjuvant control group (Figure 4c), with the rNetB-
supplemented toxoid vaccine reducing the number of
birds with lesions by 67% and the average lesion score
by 74%. Birds immunised with rNetB alone had the
highest levels of anti-NetB IgY antibodies (Figure 3c).
Similar to the previous vaccination trial, chickens
immunised with bacterin had very low NetB-specific
antibody levels while the group vaccinated with bacterinsupplemented with rNetB had higher levels compared to
the adjuvant control group. Birds immunised with toxoid
or toxoid with rNetB had similar levels of anti-NetB IgY
antibody (Figure 3c) although only toxoid with rNetB
was significantly higher (p < 0.05) compared to the adju-
vant control group.
Discussion
This study has evaluated whether NetB, a major viru-
lence factor in necrotic enteritis, is an effective protect-
ive antigen when used as a subunit vaccine or as a
supplement to either traditional bacterin or toxoid vac-
cines. rNetB alone was protective against a mild chal-
lenge with a virulent C. perfringens strain, but was not
sufficient to protect against a heavy in-feed challenge.
Immunisation with bacterin or cell free toxoid
supplemented with rNetB significantly protected birds
against necrotic enteritis following a heavy challenge
with a heterologous strain of C. perfringens (Figure 4b,c).
We conclude that rNetB has considerable potential for















































Figure 4 Lesion scores of broiler chickens immunized with clostridial proteins. Chickens were immunized subcutaneously with the
indicated vaccines on days 7 and 17, challenged with C. perfringens, and the lesions scores assessed at day 28. The solid horizontal bars represent
the average lesion score in each group. Intestinal lesions in the small intestine (duodenum to ileum) were scored as previously reported: 0, no
gross lesions; 1, thin or friable walls; 2, focal necrosis or ulceration (1 to 5 foci); 3, focal necrosis or ulceration (6 to 15 foci); 4, focal necrosis or
ulceration (16 or more foci); 5, patches of necrosis 2 to 3 cm long; 6, diffuse necrosis typical of field cases. (a) Birds were immunized and
challenged orally with EHE-NE18 (days 24 and 25). (b) Birds were immunized and challenged in-feed with EHE-NE18 (days 26 and 27). (c) Birds
were immunized and challenge in-feed with WER-NE36 (days 26 and 27). Error bars represent SEM.
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used cell free toxoids as vaccines [22-24]. Saleh et al.
[22] used two C. perfringens isolates from diseased birds
(type A and C) to generate three toxoid vaccines (type
A, type C, and type A plus type C). A significant de-
crease in disease was observed with all three toxoid vac-
cines, with the highest protection coming from the
combined type A and C toxoid. The birds immunised
with this toxoid also had higher antibody titres com-
pared to the other toxoid vaccines. Other studies have
used toxoids to immunise broiler breeder hens, on the
premise that they will develop maternal antibodies that
are transferred to the broiler progeny [23,24]. Lovland
et al. [24] immunized birds with type A and C cell free
toxoid and found that the type C toxoid protected pro-
geny better than type A. For both toxoids, the level of
anti-alpha-toxin IgY antibodies was monitored in the
hens and in day old progeny. The antibody titres in vac-
cinated birds were higher than those in unvaccinatedhens and the data suggested a protective effect on the
progeny against subclinical necrotic enteritis. However,
in their study birds immunised with the type C toxoid
had lower anti-alpha-toxin IgY antibody levels, but gave
the better protective effect. This result may be due to
the type C strain also having higher levels of protective
antigens. While the NetB status of the strains used to
produce the cell-free toxoids in these studies is not
known, it is unlikely that the strains that were used pro-
duced NetB since both strains were isolated from mam-
mals [24] and there is only one report of a NetB positive
C. perfringens being isolated from an animal other than
poultry [17].
A similar study by Crouch et al. [23] immunised
broiler layer hens from Germany and Italy with the com-
mercially available necrotic enteritis vaccine (NetVax™).
The safety and efficacy of the C. perfringens type A
alpha-toxoid was investigated. Again, the NetB status of
the strain used to prepare the vaccine was not reported,
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isolated from cattle. Vaccination resulted in a significant
increase in anti-alpha-toxin antibody in the hens and
antibodies were detected in the progeny. In contrast to
the previous study [24], which detected C. perfringens at
greater than 4 × 104 CFU/g, chicks from NetVax™ vacci-
nated hens had no detectable levels of C. perfringens.
The absence of C. perfringens cells in chicks from vacci-
nated hens suggests that maternal vaccination with
NetVax™ reduces the ability of the bacteria to colonise
the gastrointestinal tract of chickens.
In our study, the addition of rNetB to bacterin or tox-
oid preparations from a NetB-producing C. perfringens
strain significantly lowered the average lesion score com-
pared to the adjuvant control. Birds immunized with
bacterin had low titres of anti-NetB antibody, suggesting
that the native NetB protein is in low abundance in
these preparations (Figure 3b,c). In vitro grown cultures
contain too little NetB to induce a protective immune
response, hence supplementation with exogenous re-
combinant NetB was required to induce a significant
anti-NetB immune response.
A recent study investigated the immunoprotective po-
tential of native culture supernatants from disease and
non-disease derived C. perfringens isolates [25]. Of the
eight strains tested, two supernatants provided full and
partial protection (strains 23 (NetB+) and 48 (NetB-),
respectively). The authors concluded that neither alpha-
toxin nor NetB were solely immunoprotective. Unfortu-
nately, the sera from the vaccinated birds were not
analysed to identify the possible protective antigens, includ-
ing NetB and alpha-toxin. Our results are in agreement
with this study; we confirmed that rNetB alone was not
highly immunoprotective against moderate C. perfringens
challenge and demonstrated that supplemented rNetB, in
conjunction with other antigens, increased the protective
response compared to native antigens. This result is not
surprising since C. perfringens infections are multifactorial
and most clostridial vaccines are made up of a cocktail of
protective antigens, most often cell free toxoids, rather than
a single subunit based vaccine.
Analysis of the convalescent sera from birds chal-
lenged with strains EHE-NE18 and WER-NE36 indicated
that NetB IgY antibodies were generated during infec-
tion, which is in agreement with a study that looked at
both alpha-toxin and NetB antibody levels in birds that
have been experimentally challenged and birds from nat-
ural outbreaks [26]. That study found that challenged
birds had a peak anti-NetB IgY antibody level 7 days
post-challenge, after which it dramatically dropped back
to unchallenged control levels 14 days post-infection.
The results from our work and Lee et al. [26] highlight
the importance of NetB as a protective antigen and its
significance in disease.In this study rNetB, when used as a subunit vaccine,
was protective against oral gavage C. perfringens chal-
lenge, but not against a more severe challenge. This re-
sult is similar to a recent study where birds vaccinated
with rNetB had a significant decrease in lesion score
compared to the adjuvant control [18]. These authors
investigated the role of cellular immunity in protection
against C. perfringens/Eimeria maxima co-infection and
found that vaccination with ISA 71 VG adjuvant plus re-
combinant C. perfringens antigens reduced transcripts
of proinflamatory cytokines in intestinal intraepithelial
lymphocytes. Other recombinant antigens including alpha-
toxin, pyruvate:ferredoxin oxidoreductase, a hypothetical
protein, glyceraldehyde-3-phosphate dehydrogenase, fruc-
tose 1,6-biphosphate aldolase, endo-β-N-acetylglucosami-
nidase, and phosphoglyceromutase have also been shown
to significantly protect birds from necrotic enteritis
[7,13,18]. The role of alpha-toxin in immunity has been
studied extensively and it has been shown to confer vari-
able levels of protection [7-9,13,23,24,27]. It is clear that
there is a growing body of evidence that other antigens,
other than alpha-toxin, can confer protection against
disease [11-13,26,28]. NetB can be added to the list of pro-
tective antigens against necrotic enteritis [18].
The findings in this study represent the first steps to-
wards the development of an effective vaccine against
necrotic enteritis in chickens. The vaccination regime
used in the experiments is unlikely to be appropriate for
widespread use in broiler chicks because of the multiple
handling of individual birds required. A more industry
appropriate regime would be to vaccinate the breeder
hens, such as used in other studies [23,24] to induce
protection in progeny chicks; or vaccine delivery in feed,
water, or aerosolized, but that would require sophisti-
cated adjuvant and delivery technology.
In conclusion, we have shown that rNetB immunization
can significantly protect birds against disease, but not
against a severe challenge. The greatest protection ob-
served in this study came from birds immunized with cell
free toxoid or bacterin supplemented with rNetB; these
“enhanced toxoids” may be suitable candidates for use in
the poultry industry in the near future.
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